1. First‐in‐Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer. (4th March 2019) Authors: He, Aiwu Ruth; Cohen, Roger B.; Denlinger, Crystal S.; Sama, Ashwin; Birnbaum, Ariel; Hwang, Jimmy; Sato, Takami; Lewis, Nancy; Mynderse, Michelle; Niland, Michele; Giles, Jennifer; Wallin, Johan; Moser, Brian; Zhang, Wei; Walgren, Richard; Plimack, Elizabeth R. Journal: Oncologist Issue: Volume 24:Number 9(2019) Page Start: e930 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Issue 10277 (6th March 2021) Authors: Mato, Anthony R; Shah, Nirav N; Jurczak, Wojciech; Cheah, Chan Y; Pagel, John M; Woyach, Jennifer A; Fakhri, Bita; Eyre, Toby A; Lamanna, Nicole; Patel, Manish R; Alencar, Alvaro; Lech-Maranda, Ewa; Wierda, William G; Coombs, Catherine C; Gerson, James N; Ghia, Paolo; Le Gouill, Steven; Lewis, Da... Journal: Lancet Issue: Volume 397:Issue 10277(2021) Page Start: 892 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Β2‐Adrenoreceptor Agonists, Montelukast, and Parkinson Disease Risk. Issue 5 (23rd March 2023) Authors: Liu, Bojing; Svenningsson, Per; Ludvigsson, Jonas F.; Lundholm, Cecilia; Wallin, Johan; Larsson, Henrik; Sjölander, Arvid; Williams, Dylan M.; Pedersen, Nancy L.; Wirdefeldt, Karin Journal: Annals of neurology Issue: Volume 93:Issue 5(2023) Page Start: 1023 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗